Clinical Trial Update: A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating CARDIOLITE® in pediatric Kawasaki disease has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Drugs mentioned

• CARDIOLITE (TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE)

Snippet

Sponsor: Lantheus Medical Imaging | Conditions: Kawasaki Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-12-06